Reich, K.; Simpson, E. L.; Langley, R.; Warren, R. B.; Costanzo, A.; Saeki, H.; Almgren, P.; Gjerum, L.; Carlsson, A.; Gooderham, M.; Pinter, A.; de Bruin-Weller, M.; Blauvelt, A. Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest. J of Skin 2022, 6, s79.